Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2017-11-13 Capital/Financing Update
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes details about the securities being registered, the offering, and related legal and financial information. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or management report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not just an announcement or a brief notice.
2017-11-13 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q3 2017
2017-11-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 8, 2017. It specifically reports the issuance of a press release containing financial results for the third quarter ended September 30, 2017. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length of the document is 3668 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results rather than the results themselves. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results via a press release.
2017-11-08 English
Regulatory Filings 2017
Regulatory Filings
2017-10-31 English
SC 13G/A
Major Shareholding Notification
2017-10-27 English
FORM 3 SUBMISSION
Director's Dealing
2017-10-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.